Recce Pharmaceuticals Boosts Cash with A$3.7 Million Tax Refund Ahead of Phase 3 Trials
Recce Pharmaceuticals has received a significant A$3.7 million income tax refund from the Australian Taxation Office, strengthening its cash position to approximately A$33.1 million as it prepares for critical Phase 3 clinical milestones.
- A$3.7 million tax refund from FY2025 R&D expenditure
- Pro-forma cash position rises to around A$33.1 million
- Upcoming A$7.5 million R&D Tax Incentive rebate expected
- Recent capital raise and Share Purchase Plan underway
- Funds support advancing Phase 3 clinical trials
Significant Tax Refund Strengthens Financial Position
Recce Pharmaceuticals (ASX:RCE) has secured an income tax refund of A$3,667,427 from the Australian Taxation Office for the financial year ending 30 June 2025. This refund primarily relates to overseas R&D expenditure of A$3.57 million, with an additional A$95,826 paid as interest by the ATO. The inflow boosts Recce’s liquidity as it advances its pipeline of synthetic anti-infectives targeting antibiotic-resistant infections.
Cash Reserves Bolstered by Recent Capital Raising
Combined with proceeds from a recent institutional placement that raised approximately A$4 million, Recce’s pro-forma cash position now stands at around A$33.1 million, up from A$29.5 million. The company has also launched a Share Purchase Plan opening on 6 July 2026, aiming to raise up to an additional A$4 million on similar terms. These funds are earmarked to support key Phase 3 clinical trial milestones, underpinning Recce’s development strategy.
Anticipated R&D Rebate for FY2026
Looking ahead, Recce expects to receive a further R&D Tax Incentive rebate from the ATO for the financial year ending 30 June 2026, estimated at approximately A$7.5 million. This anticipated rebate, while subject to confirmation, would provide a substantial non-dilutive funding boost to the company’s ongoing research and development efforts.
Pipeline Progress and Market Recognition
Recce is developing three patented synthetic polymer anti-infectives: RECCE® 327, RECCE® 435, and RECCE® 529, targeting serious bacterial and viral infections including antibiotic-resistant strains. The World Health Organization has recognised these candidates on its list of antibacterial products in clinical development for priority pathogens. Notably, the FDA granted RECCE 327 Qualified Infectious Disease Product designation, conferring Fast Track status and a decade of market exclusivity post-approval.
Funding Positioned to Support Clinical Milestones
The strengthened cash reserves position Recce to maintain momentum in its Phase 3 trials, including pivotal studies for diabetic foot infections and other serious infections. The company’s automated manufacturing facility supports these clinical activities, ensuring supply continuity. With the combined impact of the tax refund, capital raise, and expected R&D rebate, Recce is better placed to navigate the costly late-stage clinical development phase.
Bottom Line?
Recce’s improved cash position from tax refunds and capital raises provides a firmer footing for upcoming Phase 3 trial milestones, but delivery on clinical progress remains the critical next step.
Questions in the middle?
- How will the expected A$7.5 million R&D rebate for FY2026 impact Recce’s funding runway?
- What are the timelines and key endpoints for the upcoming Phase 3 clinical trials?
- How might the Share Purchase Plan uptake influence Recce’s capital structure and investor base?
